Boston-based therapeutics company Indomo launched out of stealth with $25 million in funding to develop ClearPen, an at-home investigational injectable therapy for inflammatory acne.WHO: Indomo is reimagining clinical dermatology with trusted science and precision technology, bringing medical-grade care into the home. A clinical-stage therapeutics company, Indomo pairs proven medicines with novel delivery systems to create fast-acting, self-administered treatments for inflammatory skin conditions. Its debut product, the ClearPen, combines an established, trusted therapeutic with a novel microneedle device for at-home acne treatment. Founded by leaders from Hims & Hers, Medtronic, and Starface, Indomo brings together deep expertise in telehealth, medical devices, and consumer skincare.WHY: Indomo plans to use the funding to advance Phase 2 clinical trials and expand its microneedle delivery platform to other skin conditions. The launch highlights the growing move toward self-administered dermatology treatments, as companies leverage biotech and medical device innovation to make specialist care more accessible.Indomo is using this capital to support its Phase 2 clinical trials and the development of its device platform. Long term, the company’s goal is to leverage its ClearPen technology to address other skin conditions historically limited to in-office care, such as keloids and hidradenitis suppurativa.